BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11706744)

  • 1. Molecular mechanisms of primary hyperparathyroidism.
    Hendy GN
    Rev Endocr Metab Disord; 2000 Nov; 1(4):297-305. PubMed ID: 11706744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathogenesis of primary hyperparathyroidism.
    Arnold A; Shattuck TM; Mallya SM; Krebs LJ; Costa J; Gallagher J; Wild Y; Saucier K
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N30-6. PubMed ID: 12412775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
    Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors.
    Hosokawa Y; Pollak MR; Brown EM; Arnold A
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3107-10. PubMed ID: 7593409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 in parathyroid disease.
    Mallya SM; Arnold A
    Front Biosci; 2000 Mar; 5():D367-71. PubMed ID: 10704427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism.
    Farnebo F; Teh BT; Dotzenrath C; Wassif WS; Svensson A; White I; Betz R; Goretzki P; Sandelin K; Farnebo LO; Larsson C
    Hum Genet; 1997 Mar; 99(3):342-9. PubMed ID: 9050920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice.
    Imanishi Y; Hosokawa Y; Yoshimoto K; Schipani E; Mallya S; Papanikolaou A; Kifor O; Tokura T; Sablosky M; Ledgard F; Gronowicz G; Wang TC; Schmidt EV; Hall C; Brown EM; Bronson R; Arnold A
    J Clin Invest; 2001 May; 107(9):1093-102. PubMed ID: 11342573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma.
    Tominaga Y; Tsuzuki T; Uchida K; Haba T; Otsuka S; Ichimori T; Yamada K; Numano M; Tanaka Y; Takagi H
    Kidney Int; 1999 Apr; 55(4):1375-83. PubMed ID: 10201002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRAD1 (cyclin D1): a parathyroid neoplasia gene on 11q13.
    Arnold A; Motokura T; Bloom T; Rosenberg C; Bale A; Kronenberg H; Ruderman J; Brown M; Kim HG
    Henry Ford Hosp Med J; 1992; 40(3-4):177-80. PubMed ID: 1483873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAJOR MOLECULAR GENETIC DRIVERS IN SPORADIC PRIMARY HYPERPARATHYROIDISM.
    Arnold A
    Trans Am Clin Climatol Assoc; 2016; 127():235-244. PubMed ID: 28066056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors.
    Costa-Guda J; Arnold A
    Mol Cell Endocrinol; 2014 Apr; 386(1-2):46-54. PubMed ID: 24035866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of Hyperparathyroidism, Including Parathyroid Cancer.
    Simonds WF
    Endocrinol Metab Clin North Am; 2017 Jun; 46(2):405-418. PubMed ID: 28476229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological correlates of hyperparathyroidism.
    Duan K; Gomez Hernandez K; Mete O
    J Clin Pathol; 2015 Oct; 68(10):771-87. PubMed ID: 26163537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathogenesis of primary hyperparathyroidism.
    Cetani F; Pardi E; Borsari S; Marcocci C
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):35-9. PubMed ID: 21985978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism.
    Alvelos MI; Vinagre J; Fonseca E; Barbosa E; Teixeira-Gomes J; Sobrinho-Simões M; Soares P
    Eur J Endocrinol; 2013 Feb; 168(2):119-28. PubMed ID: 23093699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple endocrine neoplasia type 2-associated RET proto-oncogene mutations do not contribute to the pathogenesis of sporadic parathyroid tumors.
    Willeke F; Hauer MP; Buchcik R; Gebert JF; Hahn M; Fitze G; Mechtersheimer G; Möller P; Saeger HD; Herfarth C; Schackert HK
    Surgery; 1998 Sep; 124(3):484-90. PubMed ID: 9736899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic defects associated with familial and sporadic hyperparathyroidism.
    Hendy GN; Cole DE
    Front Horm Res; 2013; 41():149-65. PubMed ID: 23652676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.
    Parfitt J; Harris M; Wright JM; Kalamchi S
    J Oral Maxillofac Surg; 2015 Jan; 73(1):194.e1-9. PubMed ID: 25511968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs in parathyroid physiopathology.
    Vaira V; Verdelli C; Forno I; Corbetta S
    Mol Cell Endocrinol; 2017 Nov; 456():9-15. PubMed ID: 27816765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathophysiology of primary hyperparathyroidism.
    Brown EM
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N24-9. PubMed ID: 12412774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.